Avantor Investor Day Presentation Deck

COVID-19 impact 2020 / 2021 Incremental vaccine revenues from viral vector, mRNA and recombinant proteins Strengthened our relationship with existing & new customers Validation of our agile & responsive business model 2022+ Durability of vaccines revenue for several years driven by boosters, global vaccination needs, pediatrics population and emerging variants Navantor™ Participation in emerging mRNA vaccines and therapies (e.g., flu vaccines) 38

View entire presentation